Tags

Type your tag names separated by a space and hit enter

Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission.
Bone Marrow Transplant. 1998 Jul; 22(1):13-9.BM

Abstract

In an effort to reduce the relapse rate after unpurged autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1), the standard conditioning regimens (cyclophosphamide/busulphan and cyclophosphamide/TBI) were intensified by adding idarubicin. Seventeen patients received a continuous infusion of 21 mg idarubicin/m2/day for 2 consecutive days in addition to the standard preparative regimen. Thirteen patients served as a historical control group. The 2-year disease-free survival (DFS) of 82% in the study group was significantly (P = 0.047) better compared to 46% DFS in the control group. The relapse rate (RR) was also significantly lower (7% vs 45%; P = 0.035) in the study group. The median time to reach a white cell count (WCC) of 0.5 x 10(9)/l was 20 days in the study group vs 17 days (P = NS) in the control group. The median time until recovery of the platelet counts to 20 x 10(9)/l was 152 days in the study group vs 57 days (P = NS) in the control group. The hypoplasia in the study group resulted in a trend towards a higher need for transfusions: a median number of 38 units of erythrocytes vs 23 units in the control group (P = NS) and 23 units of platelet vs 18 units in the control group (P = NS). This pilot study suggests that addition of idarubicin to the standard conditioning regimens may improve DFS and overall survival (OS) of patients with AML treated with ABMT in CR1. These results should be confirmed in a prospective randomized study.

Authors+Show Affiliations

Department of Internal Medicine, University Hospital St Radboud, Nijmegen, The Netherlands.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article

Language

eng

PubMed ID

9678790

Citation

Jerjis, S, et al. "Idarubicin to Intensify the Conditioning Regimens of Autologous Bone Marrow Transplantation for Patients With Acute Myeloid Leukemia in First Complete Remission." Bone Marrow Transplantation, vol. 22, no. 1, 1998, pp. 13-9.
Jerjis S, Roovers E, Muus P, et al. Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Bone Marrow Transplant. 1998;22(1):13-9.
Jerjis, S., Roovers, E., Muus, P., Schaap, N., & de Witte, T. (1998). Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Bone Marrow Transplantation, 22(1), 13-9.
Jerjis S, et al. Idarubicin to Intensify the Conditioning Regimens of Autologous Bone Marrow Transplantation for Patients With Acute Myeloid Leukemia in First Complete Remission. Bone Marrow Transplant. 1998;22(1):13-9. PubMed PMID: 9678790.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. AU - Jerjis,S, AU - Roovers,E, AU - Muus,P, AU - Schaap,N, AU - de Witte,T, PY - 1998/7/25/pubmed PY - 1998/7/25/medline PY - 1998/7/25/entrez SP - 13 EP - 9 JF - Bone marrow transplantation JO - Bone Marrow Transplant VL - 22 IS - 1 N2 - In an effort to reduce the relapse rate after unpurged autologous bone marrow transplantation (ABMT) in patients with acute myeloid leukemia (AML) in first complete remission (CR1), the standard conditioning regimens (cyclophosphamide/busulphan and cyclophosphamide/TBI) were intensified by adding idarubicin. Seventeen patients received a continuous infusion of 21 mg idarubicin/m2/day for 2 consecutive days in addition to the standard preparative regimen. Thirteen patients served as a historical control group. The 2-year disease-free survival (DFS) of 82% in the study group was significantly (P = 0.047) better compared to 46% DFS in the control group. The relapse rate (RR) was also significantly lower (7% vs 45%; P = 0.035) in the study group. The median time to reach a white cell count (WCC) of 0.5 x 10(9)/l was 20 days in the study group vs 17 days (P = NS) in the control group. The median time until recovery of the platelet counts to 20 x 10(9)/l was 152 days in the study group vs 57 days (P = NS) in the control group. The hypoplasia in the study group resulted in a trend towards a higher need for transfusions: a median number of 38 units of erythrocytes vs 23 units in the control group (P = NS) and 23 units of platelet vs 18 units in the control group (P = NS). This pilot study suggests that addition of idarubicin to the standard conditioning regimens may improve DFS and overall survival (OS) of patients with AML treated with ABMT in CR1. These results should be confirmed in a prospective randomized study. SN - 0268-3369 UR - https://www.unboundmedicine.com/medline/citation/9678790/Idarubicin_to_intensify_the_conditioning_regimens_of_autologous_bone_marrow_transplantation_for_patients_with_acute_myeloid_leukemia_in_first_complete_remission_ L2 - https://doi.org/10.1038/sj.bmt.1701279 DB - PRIME DP - Unbound Medicine ER -